Study of Tasfygo for bile duct cancer with FGFR2 gene change
Part of Cancer, Digestive system clinical trials.
This study is watching people with a certain type of bile duct cancer that has a specific gene change (FGFR2 fusion). It looks at what happens when they take the drug Tasfygo after their cancer did not respond to chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with bile duct cancer that cannot be removed by surgery.
- Your cancer has a specific change in the FGFR2 gene (called a 'fusion').
- You have already had chemotherapy, and your cancer kept growing or came back afterward.
- You have not taken the drug Tasfygo before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
This trial tests a combination of surufatinib (a targeted drug) plus immunotherapy and chemotherapy for people with bile duct or gallbladder cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.